Logo do repositório
 
Publicação

Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant

2007-03-23Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorFernandes, Natércia
dc.contributor.authorFigueiredo, Paula
dc.contributor.authorRosário, Virgilio Estólio do
dc.contributor.authorCravo, Pedro
dc.contributor.institutionCentro de Malária e outras Doenças Tropicais (CMDT)
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.pblBioMed Central (BMC)
dc.date.accessioned2021-05-06T22:40:42Z
dc.date.available2021-05-06T22:40:42Z
dc.date.issued2007-03-23
dc.description.abstractBACKGROUND: Plasmodium falciparum is the predominant human malaria species in Mozambique and a lead cause of mortality among children and pregnant women nationwide. Sulphadoxine/pyrimethamine (S/P) is used as first line antimalarial treatment as a partner drug in combination with artesunate. METHODS: A total of 92 P. falciparum-infected blood samples, from children with uncomplicated malaria attending the Centro de Saude de Bagamoyo in the Province of Maputo-Mozambique, were screened for S/P resistance-conferring mutations in the pfdhfr and pfdhps genes using a nested mutation-specific polymerase chain reaction and restriction digestion (PCR-RFLP). The panel of genetic polymorphisms analysed included the pfdhfr 164L mutation, previously reported to be absent or rare in Africa. RESULTS: The frequency of the S/P resistance-associated pfdhfr triple mutants (51I/59R/108N) and of pfdhfr/pfdhps quintuple mutants (51I/59R/108N + 437G/540E) was 93% and 47%, respectively. However, no pfdhfr 164L mutants were detected. CONCLUSION: The observation that a considerably high percentage of P. falciparum parasites contained S/P resistance-associated mutations raises concerns about the validity of this drug as first-choice treatment in Mozambique. On the other hand, no pfdhfr 164L mutant was disclosed, corroborating the view that that this allele is still rare in Africa.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent4
dc.format.extent252511
dc.identifier.doi10.1186/1475-2875-6-35
dc.identifier.issn1475-2875
dc.identifier.otherPURE: 3631542
dc.identifier.otherPURE UUID: f6e2f75a-464a-4001-bdfe-605f11377704
dc.identifier.otherPubMed: 17378942
dc.identifier.otherPubMedCentral: PMC1950477
dc.identifier.otherORCID: /0000-0003-1675-4504/work/73915969
dc.identifier.otherScopus: 34247521013
dc.identifier.otherWOS: 000245990900001
dc.identifier.urihttp://hdl.handle.net/10362/117237
dc.identifier.urlhttps://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-6-35
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAdolescent
dc.subjectAnimals
dc.subjectAntimalarials
dc.subjectArtemisinins
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCodon
dc.subjectDihydropteroate Synthase
dc.subjectDrug Combinations
dc.subjectDrug Resistance, Multiple
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant
dc.subjectMalaria, Falciparum
dc.subjectMale
dc.subjectMozambique
dc.subjectMutation
dc.subjectPlasmodium falciparum
dc.subjectPyrimethamine
dc.subjectSesquiterpenes
dc.subjectSulfadoxine
dc.subjectTetrahydrofolate Dehydrogenase
dc.subjectJournal Article
dc.subjectResearch Support, Non-U.S. Gov't
dc.subjectGenetics
dc.subjectParasitology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAnalysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutanten
dc.typejournal article
degois.publication.titleMalaria Journal
degois.publication.volume6
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Analysis_of_sulphadoxine_pyrimethamine_resistance_conferring.pdf
Tamanho:
246.59 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IHMT: PM - Artigos em revista internacional com arbitragem científica